Indivior is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders.
Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients.
Indivior’s quarterly R&D and pipeline update can be found here.
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory Approval
Commercial Launch
-
Treatment for Opioid Use Disorder
Buprenorphine sublingual (SL) tablets
-
Treatment for Opioid Use Disorder
Buprenorphine and naloxone SL tablets
-
Treatment for Opioid Use Disorder
Buprenorphine and naloxone SL film
-
Treatment for Opioid Use Disorder
RBP-6000 Buprenorphine extended-release injection for subcutaneous use
-
Treatment for Schizophrenia
RBP-7000 Risperidone XR injection for subcutaneous use
-
Treatment for Opioid Overdose Rescue
OPNT-003 opioid receptor antagonist nalmefene nasal spray
-
Treatment for Alcohol Use Disorder
INDV-4002§ opioid receptor antagonist naltrexone nasal spray
-
Treatment for Acute Cannabinoid Overdose
INDV-5004@ cannabinoid-1 receptor antagonist
-
Treatment of Cannabis Use Disorder
AEF0117* Cannabinoid-1 receptor synthetic signaling specific inhibitor
-
Treatment for Substance Use Disorder
INDV-2000** selective orexin-1 receptor antagonist
-
Treatment for Substance Use Disorder
INDV-1000*** Gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM)
